- Can-Fite BioPharma (NYSEMKT:CANF) announces clinical development plans for candidates piclidenoson and namodenoson for this year.
- Piclidenoson:
- The Phase 3 ACRobat study in rheumatoid arthritis is currently enrolling patients. The trial is assessing the orally administered drug in a first-line setting as a replacement for standard-of-care methotrexate. A second Phase 3, Comfort, in patients with moderate-to-severe plaque psoriasis should launch this year. Both studies will support a marketing application in Europe.
- Namodenoson:
- Topline data from an ongoing Phase 2 study in advanced liver cancer should be available in H2. A Phase 2 in NAFLD/NASH is underway in Israel. Enrollment of ~60 subjects should be completed within the next 12 months.
- The company has developed a screening assay for the A3AR biomarker aimed at identifying individual patient's responsiveness to the drugs. If a direct correlation is found, it intends to commercialize its use.
- Now read: CRISPR Therapeutics: Elucidating The New CRISPR/Cas9 Exploratory Findings
Original article